vs
Side-by-side financial comparison of GRAIL, Inc. (GRAL) and WEST BANCORPORATION INC (WTBA). Click either name above to swap in a different company.
GRAIL, Inc. is the larger business by last-quarter revenue ($43.6M vs $26.9M, roughly 1.6× WEST BANCORPORATION INC). WEST BANCORPORATION INC runs the higher net margin — 39.2% vs -227.5%, a 266.7% gap on every dollar of revenue. On growth, WEST BANCORPORATION INC posted the faster year-over-year revenue change (16.6% vs 14.0%). WEST BANCORPORATION INC produced more free cash flow last quarter ($12.4M vs $-63.9M). Over the past eight quarters, GRAIL, Inc.'s revenue compounded faster (27.7% CAGR vs 17.3%).
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
West Bancorporation Inc. is a regional financial holding company headquartered in the U.S. Midwest, primarily serving markets across Iowa and Minnesota. It provides a full suite of personal and commercial banking services, including deposit accounts, mortgage loans, business lending, and wealth management solutions for individual consumers, small-to-medium enterprises, and local organizational clients.
GRAL vs WTBA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | ||
|---|---|---|
| Revenue | $43.6M | $26.9M |
| Net Profit | $-99.2M | $10.6M |
| Gross Margin | — | — |
| Operating Margin | -285.4% | 50.0% |
| Net Margin | -227.5% | 39.2% |
| Revenue YoY | 14.0% | 16.6% |
| Net Profit YoY | -2.2% | 34.8% |
| EPS (diluted) | $-2.37 | $0.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $26.9M | ||
| Q4 25 | $43.6M | $24.2M | ||
| Q3 25 | $36.2M | $25.0M | ||
| Q2 25 | $35.5M | $23.8M | ||
| Q1 25 | $31.8M | $23.1M | ||
| Q4 24 | $38.3M | $20.9M | ||
| Q3 24 | $28.7M | $20.3M | ||
| Q2 24 | $32.0M | $19.6M |
| Q1 26 | — | $10.6M | ||
| Q4 25 | $-99.2M | $7.4M | ||
| Q3 25 | $-89.0M | $9.3M | ||
| Q2 25 | $-114.0M | $8.0M | ||
| Q1 25 | $-106.2M | $7.8M | ||
| Q4 24 | $-97.1M | $7.1M | ||
| Q3 24 | $-125.7M | $6.0M | ||
| Q2 24 | $-1.6B | $5.2M |
| Q1 26 | — | 50.0% | ||
| Q4 25 | -285.4% | 39.6% | ||
| Q3 25 | -346.2% | 45.8% | ||
| Q2 25 | -446.9% | 43.4% | ||
| Q1 25 | -482.5% | 43.4% | ||
| Q4 24 | -358.0% | 30.9% | ||
| Q3 24 | -640.5% | 36.6% | ||
| Q2 24 | -5133.8% | 32.6% |
| Q1 26 | — | 39.2% | ||
| Q4 25 | -227.5% | 30.7% | ||
| Q3 25 | -245.8% | 37.3% | ||
| Q2 25 | -320.7% | 33.5% | ||
| Q1 25 | -333.6% | 34.0% | ||
| Q4 24 | -253.8% | 34.0% | ||
| Q3 24 | -438.7% | 29.3% | ||
| Q2 24 | -4958.8% | 26.5% |
| Q1 26 | — | $0.61 | ||
| Q4 25 | $-2.37 | $0.44 | ||
| Q3 25 | $-2.46 | $0.55 | ||
| Q2 25 | $-3.18 | $0.47 | ||
| Q1 25 | $-3.10 | $0.46 | ||
| Q4 24 | $-1.49 | $0.41 | ||
| Q3 24 | $-3.94 | $0.35 | ||
| Q2 24 | $-51.06 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | ||
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $249.7M | $362.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.6B | $270.7M |
| Total Assets | $2.9B | $4.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $362.0M | ||
| Q4 25 | $249.7M | $471.1M | ||
| Q3 25 | $126.9M | $232.9M | ||
| Q2 25 | $127.4M | $345.2M | ||
| Q1 25 | $133.9M | — | ||
| Q4 24 | $214.2M | $243.5M | ||
| Q3 24 | $853.6M | — | ||
| Q2 24 | $958.8M | — |
| Q1 26 | — | $270.7M | ||
| Q4 25 | $2.6B | $266.0M | ||
| Q3 25 | $2.2B | $255.1M | ||
| Q2 25 | $2.3B | $240.9M | ||
| Q1 25 | $2.4B | $237.9M | ||
| Q4 24 | $2.5B | $227.9M | ||
| Q3 24 | $2.6B | $235.4M | ||
| Q2 24 | $2.7B | $223.9M |
| Q1 26 | — | $4.0B | ||
| Q4 25 | $2.9B | $4.1B | ||
| Q3 25 | $2.6B | $4.0B | ||
| Q2 25 | $2.7B | $4.1B | ||
| Q1 25 | $2.8B | $4.0B | ||
| Q4 24 | $3.0B | $4.0B | ||
| Q3 24 | $3.1B | $4.0B | ||
| Q2 24 | $3.3B | $4.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | ||
|---|---|---|
| Operating Cash FlowLast quarter | $-63.8M | $12.9M |
| Free Cash FlowOCF − Capex | $-63.9M | $12.4M |
| FCF MarginFCF / Revenue | -146.5% | 46.0% |
| Capex IntensityCapex / Revenue | 0.2% | 1.8% |
| Cash ConversionOCF / Net Profit | — | 1.22× |
| TTM Free Cash FlowTrailing 4 quarters | $-299.9M | $79.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $12.9M | ||
| Q4 25 | $-63.8M | $46.5M | ||
| Q3 25 | $-63.2M | $11.4M | ||
| Q2 25 | $-77.0M | $13.5M | ||
| Q1 25 | $-95.0M | $9.7M | ||
| Q4 24 | — | $39.8M | ||
| Q3 24 | $-104.6M | $12.9M | ||
| Q2 24 | $-171.8M | $10.0M |
| Q1 26 | — | $12.4M | ||
| Q4 25 | $-63.9M | $43.2M | ||
| Q3 25 | $-63.6M | $10.8M | ||
| Q2 25 | $-77.3M | $12.8M | ||
| Q1 25 | $-95.1M | $8.3M | ||
| Q4 24 | — | $13.7M | ||
| Q3 24 | $-105.6M | $7.0M | ||
| Q2 24 | $-173.2M | $2.7M |
| Q1 26 | — | 46.0% | ||
| Q4 25 | -146.5% | 178.3% | ||
| Q3 25 | -175.8% | 43.0% | ||
| Q2 25 | -217.6% | 53.6% | ||
| Q1 25 | -298.6% | 35.7% | ||
| Q4 24 | — | 65.6% | ||
| Q3 24 | -368.4% | 34.2% | ||
| Q2 24 | -541.7% | 14.0% |
| Q1 26 | — | 1.8% | ||
| Q4 25 | 0.2% | 13.7% | ||
| Q3 25 | 1.1% | 2.6% | ||
| Q2 25 | 1.0% | 3.2% | ||
| Q1 25 | 0.2% | 6.5% | ||
| Q4 24 | — | 125.3% | ||
| Q3 24 | 3.4% | 29.4% | ||
| Q2 24 | 4.3% | 37.1% |
| Q1 26 | — | 1.22× | ||
| Q4 25 | — | 6.26× | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 1.70× | ||
| Q1 25 | — | 1.24× | ||
| Q4 24 | — | 5.61× | ||
| Q3 24 | — | 2.17× | ||
| Q2 24 | — | 1.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GRAL
| Screening Revenue | $42.3M | 97% |
| Developmental Services Revenue | $1.3M | 3% |
WTBA
Segment breakdown not available.